Journal article
Sekundärprävention nach ischämischem zerebralem Insult Die ESPRIT-Studie: niedrig dosierte Antikoagulation, Kombinationstherapie mit Acetylsalicylsäure/Dipyridamol oder Monotherapie mit Acetylsalicylsäure?
Abstract
The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0–3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and …
Authors
Gorter JW; De Schryver ELLM; Algra A
Journal
Der Nervenarzt, Vol. 70, No. 4, pp. 368–370
Publisher
Springer Nature
Publication Date
April 1999
DOI
10.1007/s001150050451
ISSN
0028-2804